# Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

> **NCT04365101** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Celularity Incorporated** · enrollment: 86 (actual)

## Conditions studied

- Coronavirus
- Coronavirus Infection
- Severe Acute Respiratory Syndrome Coronavirus 2
- Pneumonia
- Pneumonia, Viral
- Lung Diseases
- Respiratory Tract Disease
- Respiratory Tract Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Disease
- Immunologic Disease
- ARDS
- Immunologic Factors
- Physiological Effects of Drugs
- Antiviral Agents
- Anti-infective Agents
- Analgesics
- Antimetabolites, Antineoplastic

## Interventions

- **BIOLOGICAL:** CYNK-001

## Key facts

- **NCT ID:** NCT04365101
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-13
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365101, "Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04365101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*